Aiello Paola, Consalvi Sara, Poce Giovanna, Raguzzini Anna, Toti Elisabetta, Palmery Maura, Biava Mariangela, Bernardi Marco, Kamal Mohammad A, Perry George, Peluso Ilaria
Research Centre for Food and Nutrition, Council for Agricultural Research and Economics (CREA-AN), Rome, Italy; Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Italy; Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain.
Department of Chemistry and Drug Technologies, University "La Sapienza", Rome, Italy.
Semin Cancer Biol. 2021 Feb;69:150-165. doi: 10.1016/j.semcancer.2019.08.029. Epub 2019 Aug 24.
Application of nanotechnologies to cancer therapy might increase solubility and/or bioavailability of bioactive compounds of natural or synthetic origin and offers other potential benefits in cancer therapy, including selective targeting. In the present review we aim to evaluate in vivo studies on the anticancer activity of nanoparticles (NPs) obtained from food-derived flavonoids. From a systematic search a total of 60 studies were identified. Most of the studies involved the flavanol epigallocatechin-3-O-gallate and the flavonol quercetin, in both delivery and co-delivery (with anti-cancer drugs) systems. Moreover, some studies investigated the effects of other flavonoids, such as anthocyanins aglycones anthocyanidins, flavanones, flavones and isoflavonoids. NPs inhibited tumor growth in both xenograft and chemical-induced animal models of cancerogenesis. Encapsulation improved bioavailability and/or reduced toxicity of both flavonoids and/or co-delivered drugs, such as doxorubicin, docetaxel, paclitaxel, honokiol and vincristine. Moreover, flavonoids have been successfully applied in molecular targeted nanosystems. Selectivity for cancer cells involves pH- and/or reactive oxygen species-mediated mechanisms. Furthermore, flavonoids are good candidates as drug delivery for anticancer drugs in green synthesis systems. In conclusion, although human studies are needed, NPs obtained from food-derived flavonoids have promising anticancer effects in vivo.
将纳米技术应用于癌症治疗可能会提高天然或合成来源的生物活性化合物的溶解度和/或生物利用度，并在癌症治疗中提供其他潜在益处，包括选择性靶向。在本综述中，我们旨在评估从食物来源的黄酮类化合物获得的纳米颗粒（NPs）抗癌活性的体内研究。通过系统检索，共鉴定出60项研究。大多数研究涉及黄烷醇表没食子儿茶素-3-O-没食子酸酯和黄酮醇槲皮素，用于递送和共递送（与抗癌药物）系统。此外，一些研究调查了其他黄酮类化合物的作用，如花色苷苷元花青素、黄烷酮、黄酮和异黄酮。纳米颗粒在异种移植和化学诱导的癌症发生动物模型中均抑制肿瘤生长。包封提高了黄酮类化合物和/或共递送药物（如阿霉素、多西他赛、紫杉醇、厚朴酚和长春新碱）的生物利用度和/或降低了其毒性。此外，黄酮类化合物已成功应用于分子靶向纳米系统。对癌细胞的选择性涉及pH和/或活性氧介导的机制。此外，黄酮类化合物是绿色合成系统中抗癌药物递送的良好候选物。总之，尽管需要人体研究，但从食物来源的黄酮类化合物获得的纳米颗粒在体内具有有前景的抗癌作用。
